XHKG
2159
Market cap56mUSD
Oct 09, Last price
1.66HKD
1D
-1.19%
1Q
6.41%
IPO
-61.48%
Name
Mediwelcome Healthcare Management & Technology Inc
Chart & performance
P/E
38.48
P/S
0.82
EPS
0.04
Div yield, %
—
Shrs. gr., 5y
2.66%
Rev. gr., 5y
1.60%
Revenues
468m
+45.55%
Net income
10m
P
CFO
3m
P
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
As an investment holding entity, Mediwelcome Healthcare Management & Technology Inc. delivers comprehensive marketing solutions for the healthcare sector within the People's Republic of China. Its service portfolio encompasses medical conference organization, patient education and screening programs, along with strategic marketing and advisory support. Additionally, the company provides Contract Research Organization (CRO) services, specifically focusing on patient recruitment and clinical data gathering. Furthermore, Mediwelcome manages a mobile application that facilitates internet hospital functionalities, including virtual follow-up consultations for physicians' current patients and electronic prescription services. Its diverse client base includes pharmaceutical firms, medical associations, and various foundations. Established in 2000, Mediwelcome Healthcare Management & Technology Inc. maintains its headquarters in Beijing, China.
Key people
Weimin Yang
Executive Vice Chairman of the Board · since 2019
Xingri Yin
Vice President
Chengying Deng
Chief Financial Officer, Executive Director · since 2025
Wei Shi
Executive Chairman of the Board
Liang Wang
Chief Executive Officer, Executive Director · since 2019
Siu Wai Tsoi
Joint Company Secretary · since 2023
Luyang Zhao
Vice President - Human Resources, Joint Company Secretary · since 2019
Xia Liu
Non-Executive Director · since 2019
Huilin Chen
Non-Executive Independent Director · since 2025
Ruilin Song
Non-Executive Independent Director · since 2020
Zheng Wang
Non-Executive Independent Director · since 2020
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | |
| Income | |||||||||
Revenues | |||||||||
Cost of revenue | |||||||||
Unusual Expense (Income) | |||||||||
NOPBT | |||||||||
NOPBT Margin | |||||||||
Operating Taxes | |||||||||
Tax Rate | |||||||||
NOPAT | |||||||||
Net income | |||||||||
Dividends | |||||||||
Dividend yield | |||||||||
Proceeds from repurchase of equity | |||||||||
BB yield | |||||||||
| Debt | |||||||||
Debt current | |||||||||
Long-term debt | |||||||||
Deferred revenue | |||||||||
Other long-term liabilities | |||||||||
Net debt | |||||||||
| Cash flow | |||||||||
Cash from operating activities | |||||||||
CAPEX | |||||||||
Cash from investing activities | |||||||||
Cash from financing activities | |||||||||
FCF | |||||||||
| Balance | |||||||||
Cash | |||||||||
Long term investments | |||||||||
Excess cash | |||||||||
Stockholders' equity | |||||||||
Invested Capital | |||||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | |||||||||
Price | |||||||||
Market cap | |||||||||
EV | |||||||||
EBITDA | |||||||||
EV/EBITDA | |||||||||
Interest | |||||||||
Interest/NOPBT | |||||||||